Researchers have uncovered the gene at the root of a human blood group that has remained a mystery for the past 60 years. They showed that a genetic deletion on this gene is responsible for the lack of this blood group in some people.
With the discovery of the gene behind the Vel blood group, medical scientists can now develop a more reliable DNA test to identify people who lack this group. This will reduce the risk of severe, and sometimes life threatening, destruction of the Vel-positive donor red blood cells in patients with antibodies against Vel.
The genetic basis of nearly all 34 blood group systems has been resolved over the past century, but identification of the underlying gene of the Vel blood group has withstood persistent attempts since it was first identified 60 years ago. It is estimated that one in 5000 people are Vel-negative, and routine blood transfusions for patients with antibodies against Vel can lead to kidney failure and even death.
"This is really exciting as it shows how the power of modern genomics technologies can directly benefit patient care," says Professor Willem Ouwehand , who heads one of the NHS Blood and Transplant research teams at both the University of Cambridge and the Wellcome Trust Sanger Institute. "This is also a milestone in blood group genetics and the end of long and astounding journey of discoveries in blood group genetics which started with Landsteiner from Austria and Fisher, Coombs and Morgan from England."
The discovery by the team would not have been possible without the colleagues from the blood transfusion services of Denmark, England and the Netherlands who undertook the Herculean effort of identifying the 65 individuals that lacked the Vel blood group by testing the red blood cells from nearly 350,000 donors with antibodies against Vel.
They then sequenced the coding fraction of the genomes of five donors who lack the Vel group to identify the underlying gene.
The team showed that the gene SMIM1 malfunctions in Vel-negative people. SMIM1 is found on chromosome 1 and specifies a small protein, five times smaller than the average human protein. This provides a direct explanation why a discovery by other routes has proven so challenging.
"It has been a remarkable feat to go from gene discovery to function in less than two months", continues Professor Ouwehand.
Current testing for Vel-negative people can be inaccurate but identifying this new role for the gene will make it easier to identify people who lack Vel. The Sanquin Blood Supply research laboratories in Amsterdam and the NHS Blood and Transplant Centre in Cambridge are currently working together to develop a new and affordable DNA test to efficiently identify people who lack the Vel group.
"We already knew of 75 genomic regions that are associated with the haemoglobin levels and other red blood cell traits, but we quickly realised that the SMIM1 gene identified in our study is the same as one of these associated regions," said Dr Pim van der Harst from Groningen University in the Netherlands who led the GWAS analysis for red cell traits in nearly 100,000 individuals. "We had already assumed that a gene in this region of chromosome 1 played a role in the life of red blood cells, but we now have conclusive evidence that it is SMIM1
"We have shown that this gene controls a protein in the membrane of red blood cells. Switching off the SMIM1 gene in zebrafish showed a remarkable reduction in the number of red cells formed and caused anaemia in the fish".
The team observed that the common variant identified by the red blood cell study has a strong effect on how well the SMIM1 gene functions. This not only explains why the level of the Vel blood group varies so extensively in the population, but is also makes it extremely plausible that the Smim1 protein influences haemoglobin levels of red blood cells.
A low haemoglobin level confers a risk of anaemia, which is one of the most frequent reasons for an individual to visit their doctor. The team are pursuing further research to deduce how Smim1 protein regulates red blood cell formation.
"As the molecular machinery underlying red blood cell formation has been researched for decades in fish, mice and man, our discovery that a gene which was considered hypothetical until recently actually controls a red blood cell membrane protein with an important role in the regulation of haemoglobin levels is astonishing," says Professor Ellen van der Schoot from the Sanquin research laboratories in Amsterdam. "A better understanding of how the SMIM1 gene is regulated is important and this effort will greatly benefit from the Blueprint project which will be releasing its results on the biology of blood cells and their precursors this year."
"We have worked for nearly a decade to identify the donors across England that lack the Vel blood group so that we can provide matched and safe blood to patients with antibodies against Vel" says Mr Malcolm Needs from NHS Blood and Transplant in Tooting, London. "The discovery of the SMIM1 gene was achieved so quickly and it is truly amazing to see how medical genomics is changing the care landscape for NHS patients."
Notes to Editors
Ana Cvejic, Lonneke Haer-Wigman, Jonathan C Stephens et al. (2013) 'SMIM1 underlies the Vel blood group and influences red blood cell traits' Published in Nature Genetics online 07 April 2013. doi:10.1038/ng.2603
This study was supported by the British Heart Foundation, European Commission, Medical Research Council, National Institute for Health Research, NHS Blood and Transplant and the Wellcome Trust.
Participating centresDepartment of Haematology, University of Cambridge, Cambridge, UK.
Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands.
Professor van der Schoot is a consultant to the Sanquin Blood Supply Foundation in the Netherlands which ensures the safe and efficient blood and platelet supply for the Dutch Healthcare system. Sanquin also develops and produces pharmaceutical products, conducts high-quality scientific research, and develops and performs a multitude of diagnostic services. http://www.sanquin.nl
Professor Ouwehand is a consultant Haematologist for NHS Blood and Transplant.
NHS Blood and Transplant (NHSBT) is a joint England and Wales Special Health Authority. Its remit includes the provision of a reliable, efficient supply of blood and associated services to the NHS in England and North Wales. It is also the organ donor organisation for the UK and is responsible for matching and allocating donated organs. Eight research themes make up NHSBT's planned Research & Development Strategy. The main research sites, in collaboration with University partners, are Cambridge, Oxford, London and Bristol, with specialist activity in Birmingham and Liverpool. NHSBT, http://www.nhsbt.nhs.uk/
The mission of the University of Cambridge is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. It admits the very best and brightest students, regardless of background, and offers one of the UK's most generous bursary schemes. The University of Cambridge's reputation for excellence is known internationally and reflects the scholastic achievements of its academics and students, as well as the world-class original research carried out by its staff. Some of the most significant scientific breakthroughs occurred at the University, including the splitting of the atom, invention of the jet engine and the discoveries of stem cells, plate tectonics, pulsars and the structure of DNA. From Isaac Newton to Stephen Hawking, the University has nurtured some of history's greatest minds and has produced more Nobel Prize winners than any other UK institution with over 80 laureates. http://www.cam.ac.uk
The Wellcome Trust Sanger Institute, which receives the majority of its funding from the Wellcome Trust, was founded in 1992. The Institute is responsible for the completion of the sequence of approximately one-third of the human genome as well as genomes of model organisms and more than 90 pathogen genomes. In October 2006, new funding was awarded by the Wellcome Trust to exploit the wealth of genome data now available to answer important questions about health and disease. http://www.sanger.ac.uk
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests. http://www.wellcome.ac.uk
Contact detailsDon Powell Media Manager
Aileen Sheehy | EurekAlert!
Further reports about: > DNA > DNA test > Gates Foundation > Groningen > Health Research > Landsteiner > Medical Wellness > Molecular Biology > Molecular Target > NHS > NHSBT > Netherlands > Nobel Prize > Trust > Vel-negative > blood cell > blood flow > blood group > chromosome 1 > health services > red blood cells > supply chain > synthetic biology > transplant
Navigational view of the brain thanks to powerful X-rays
18.10.2017 | Georgia Institute of Technology
Separating methane and CO2 will become more efficient
18.10.2017 | KU Leuven
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
18.10.2017 | Materials Sciences
18.10.2017 | Physics and Astronomy
18.10.2017 | Physics and Astronomy